SeeTreat's ART.1-US Software Achieves FDA Clearance for Clinical Use

Introduction

On May 18, 2026, SeeTreat made a significant announcement regarding their ART.1-US software, which has received FDA clearance for clinical use in the United States. This groundbreaking software provides automated adaptive decision support, allowing clinicians to make timely adjustments in treatment plans. This is a monumental step forward for cancer care, especially in the realm of radiotherapy.

The Functionality of ART.1-US

SeeTreat's ART.1-US software is designed to enhance patient treatment by delivering rapid evaluations of radiotherapy doses tailored to the patient's evolving anatomy. With this innovative technology, clinical teams can determine the optimal moment to initiate a new radiotherapy plan in less than 95 seconds. The software also allows users to download clinical documentation that supports diagnostic and treatment decisions.

This tool is set to be utilized by clinics equipped with Varian or Elekta CT linear accelerators, thereby equipping hospitals across the nation with the ability to provide the most effective care possible. This is not only a technological advancement but also a move towards optimizing resources and improving patient outcomes through evidence-based practices in radiotherapy.

Collaboration with US Networks

SeeTreat has collaborated with several major US healthcare networks to facilitate early access and research on the software. These collaborations have allowed healthcare providers to experience the benefits of ART.1-US in research settings prior to its clinical rollout. As Dr. Trang Nguyen, SeeTreat's CEO, remarked, the FDA clearance represents a pivotal moment that expands their reach from the UK, Europe, and Australia to the largest radiotherapy market in the world.

Professor Jeff Siebers from the University of Virginia reiterated the importance of this software, noting that their clinical trials have illustrated how automated adaptive decision support aids clinical teams in efficiently evaluating anatomic changes during treatment. This capability is crucial for making data-driven replanning decisions that can significantly affect patient care throughout their treatment course.

The Future of Personalized Adaptive Radiotherapy

SeeTreat's mission is to make highly personalized radiotherapy accessible to all cancer patients. With the ART.1-US FDA clearance marking a new chapter, the company is eager to partner with US clinics. This collaboration aims to unlock the full potential of offline adaptive radiotherapy, allowing clinicians to provide individualized treatment plans based on real-time patient data.

With existing certifications including UKCA mark, CE mark, and Australian TGA ARTG registration, the FDA 510k clearance solidifies ART.1-US as a leading product in adaptive radiotherapy solutions, positioning SeeTreat as an integral player in global cancer treatment advancements.

Conclusion

In conclusion, the FDA clearance of SeeTreat’s ART.1-US software signifies a substantial leap forward in adaptive radiotherapy. This innovative software promises to improve patient care through timely, data-driven decision-making and efficient treatment planning. As SeeTreat embarks on this new journey, it carries a vision of broadening access to high-quality cancer treatment, helping to alleviate the burden of cancer on patients and healthcare systems alike. For more information, visit SeeTreat’s official website.